Evidence map›Paper›PMID 29636023›Full record

ArticleBMC infectious diseases2018

Mortality and treatment response amongst HIV-infected patients 50 years and older accessing antiretroviral services in South Africa.

Halima Dawood, Razia Hassan-Moosa, Nonhlanhla-Yende Zuma, Kogieleum Naidoo

Open access · goldAbstract read
In one paragraph

Article in BMC infectious diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 43 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Effect of HIV on mortality among hospitalised patients in South Africa.Southern African journal of HIV medicine · 2023
    Article
  8. Observational
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Observational
  16. Article
  17. Article
  18. Sex Differences in the Treatment of HIV.Current HIV/AIDS reports · 2020
    Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Halima DawoodCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa. halima.dawood@caprisa.org.ORCID 0000-0001-8180-6791
Razia Hassan-MoosaCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Nonhlanhla-Yende ZumaCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa.
Kogieleum NaidooCentre for the AIDS Programme of Research in South Africa (CAPRISA), Durban, South Africa. Kogie.naidoo@caprisa.org.
Centre for the AIDS Programme of Research in South Africa · ZA

Funding

TUBERCULOSIS SUPPLEMENTD43TW000231 · FIC · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI ABDOOL KARIM, QUARRAISHA · 1993 to 2014
$13.1M
FIC NIH HHS D43 TW000231PEPFAR
6 · The paper itself

Abstract

backgroundLittle is known about the clinical presentation and outcomes amongst older HIV infected populations accessing ART in sub-Saharan Africa. We compared mortality amongst HIV infected patients accessing ART that were <  50 years to those ≥50 years in Kwa-Zulu Natal, South Africa.

methodsWe undertook a retrospective review of medical records of patients that accessed HIV services at the CAPRISA AIDS Treatment program (CAT) between June 2004 to December 2012 (N = 4003). HIV infected patients, 14 years or older were enrolled. All-cause mortality and treatment response to ART in those < 50 years to those ≥50 years were compared. A Kaplan-Meier curve and log-rank test were used to compare the cumulative probability of death between the two age groups with the primary endpoint being mortality. Statistical analysis was done using SAS (version 9.4.; SAS Institute Inc., Cary, NC, USA).

resultsOf 4003 individuals, 262 (6.5%) were ≥ 50 years (older group). The median age in those ≥50 years and <  50 year was 54.5 and 32.0 years, respectively. The younger group was mainly female (64.7%). There was no difference in mortality rate, between the older (6.9/100 person-years (py), 95% confidence interval (CI): 4.7-9.6) and younger group (5.3/100 py, 95% CI: 4.7-5.8) at 60 months (p = 0.137). In the multivariable model older patients had a significantly higher risk of death compared to younger patients. (hazard ratio (HR) 1.60, 95% CI: 1.08-2.39, p = 0.019).The rate of CD4+ cell count increase was higher in those < 50 years (β = 0.34, 95% CI: 0.19-0.50, p < 0.001) with no difference in viral suppression. The older group showed significantly higher prevalence of diabetes (6.3%) and hypertension (21.5%), p < 0.001.

conclusionART initiation in older HIV infected patients was associated with a higher mortality compared to those younger than 50 years. ART immunological response was less robust in older individuals. The increase in hypertension and diabetes among older patients suggests the need to restructure and integrate primary and specialized health care services into ART services.

Indexed as

AdultAnti-Retroviral AgentsCD4 Lymphocyte CountDiabetes ComplicationsFemaleHIV InfectionsHumansHypertensionKaplan-Meier EstimateMaleMiddle AgedPrevalenceProportional Hazards ModelsRetrospective StudiesRiskSouth AfricaAnti-Retroviral AgentsAnti-retroviral treatmentHIVMortalityOlderSouth Africa

Identifiers

PMID29636023
PMCPMC5894176
OpenAlexW2797472130

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.